Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • NPI Medicare & Medicaid
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.28
    OpenPayerBilling CodesMyeloproliferative Diseases and Disorders, Poorly Differentiated NeoplasmsDRG 850-acute-leukemia-with-other-procedures
    Ask Trek AI about this page

    Acute Leukemia with Other Procedures: Inpatient Reimbursement Overview

    DRG 850 encompasses inpatient stays for acute leukemia when other significant procedures are performed, reflecting combined oncology care and procedural resource use. Correct assignment affects inpatient reimbursement under Medicare prospective payment by aligning payment with expected services and intensity of care.

    Customize your policy alerts

    Sign up for drg 850 policy alerts

    Get alerted when payer policies referencing 850 are released or updated.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    DRG 850 Overview

    DRG 850 covers inpatient admissions for patients with acute leukemia who undergo other significant procedures during the same hospital stay, typically including procedures related to chemotherapy administration, central venous access, or supportive care interventions. This Diagnosis-Related Group groups cases with resource use above routine medical management but without the presence of major complications or comorbidities that would place them in a higher-severity category. It matters for Medicare payment because it helps determine the bundled prospective payment for the hospital stay based on expected resource consumption associated with both the leukemia diagnosis and the additional procedures. Accurate coding of the procedures and clinical diagnoses is essential to assign the correct Diagnosis-Related Group and receive appropriate reimbursement.

    Table of contents

    Progress1 / 3

    Explore openpayer tools

    • Billing CodesCPT, HCPCS, DRG & more
    • Reimbursement RatesCommercial vs. Medicare rate reports
    • ProvidersHospitals & facilities
    • PayersPlans & market footprint
    • Taxonomy CodesNUCC specialty codes
    • ModifiersCPT modifiers & usage
    • Prior AuthorizationPA policies by payer & drug
    • Timely FilingFiling deadlines by payer
    • Coverage CriteriaMedical necessity by payer
    • Payer ContactsClaims, PA & appeals contacts
    View all tools

    Clinical Trials

    • Acute inpatient induction and salvage therapy optimization trials: studies in this area evaluate different intensive chemotherapy regimens, dosing strategies, or supportive-care bundles used during the initial hospitalization for newly diagnosed or relapsed acute leukemia patients who require urgent cytoreduction and marrow-directed therapy. Populations include adults and adolescents admitted for induction or salvage treatment often with high-risk cytogenetics or treatment-related marrow failure; outcomes measured are early remission rates, time to hematologic recovery, infection-related complications, transfusion requirements, and inpatient mortality. This research is highly relevant to hospital clinicians and payers because induction-phase resource use (length of stay, ICU transfers, blood products, and anti-infective therapy) drives short-term costs and quality metrics for DRG 850 admissions.
    • Comparative effectiveness and toxicity reduction studies for procedure-associated care: trials here compare strategies to reduce procedure-related morbidity such as different central venous access protocols, prophylactic antimicrobial regimens around invasive procedures, or approaches to minimize transfusion and bleeding complications during bone marrow biopsies, lumbar punctures, or placement/removal of devices. The studied populations are hospitalized acute leukemia patients undergoing diagnostic and therapeutic procedures while profoundly cytopenic; trial endpoints include procedural complication rates, need for additional interventions, bleeding/thrombosis events, and procedure-related length of stay. Findings inform clinicians on safer, cost-effective procedural pathways and help payers anticipate procedure-associated utilization and avoidable complications that increase expenditure under this DRG.
    • Post-discharge and transitional care outcomes studies focusing on readmission prevention and outpatient consolidation: these studies test models such as early discharge with ambulatory chemotherapy, structured outpatient monitoring programs, or enhanced transitional care coordination to decrease 30-day readmissions and manage complications after an acute leukemia hospitalization. Participants are patients stabilized after induction or other inpatient procedures who remain at high risk for infection, cytopenias, or treatment toxicity during the early recovery/consolidation phase; outcomes include readmission rates, emergency visits, outpatient transfusion needs, and patient-reported functioning. Results are pertinent to hospital systems and payers because reducing preventable readmissions and shifting portions of care safely to lower-cost outpatient settings can lower total episode costs and improve resource allocation for DRG 850 cases.

    Related Codes

    820-LYMPHOMA-AND-LEUKEMIA-WITH-MAJOR-O-R-PROCEDURES-WITH-MCC

    Lymphoma and Leukemia with Major O.R. Procedures with MCC: Inpatient Reimbursement Overview

    821-LYMPHOMA-AND-LEUKEMIA-WITH-MAJOR-O-R-PROCEDURES-WITH-CC

    Lymphoma and Leukemia with Major O.R. Procedures with CC: Inpatient Reimbursement Overview

    822-LYMPHOMA-AND-LEUKEMIA-WITH-MAJOR-O-R-PROCEDURES-WITHOUT-CC-MCC

    Lymphoma and Leukemia with Major O.R. Procedures without CC/MCC: Inpatient Reimbursement Overview

    823-LYMPHOMA-AND-NON-ACUTE-LEUKEMIA-WITH-OTHER-PROCEDURES-WITH-MCC

    Lymphoma and Non-Acute Leukemia with Other Procedures with MCC: Inpatient Reimbursement Overview

    824-LYMPHOMA-AND-NON-ACUTE-LEUKEMIA-WITH-OTHER-PROCEDURES-WITH-CC

    Lymphoma and Non-Acute Leukemia with Other Procedures with CC: Inpatient Reimbursement Overview

    825-LYMPHOMA-AND-NON-ACUTE-LEUKEMIA-WITH-OTHER-PROCEDURES-WITHOUT-CC-MCC

    Lymphoma and Non-Acute Leukemia with Other Procedures without CC/MCC: Inpatient Reimbursement Overview

    826-MYELOPROLIFERATIVE-DISORDERS-OR-POORLY-DIFFERENTIATED-NEOPLASMS-WITH-MAJOR-O-R-PROCEDURES-WITH-MCC

    Myeloproliferative Disorders or Poorly Differentiated Neoplasms with Major O.R. Procedures with MCC: Inpatient Reimbursement Overview

    827-MYELOPROLIFERATIVE-DISORDERS-OR-POORLY-DIFFERENTIATED-NEOPLASMS-WITH-MAJOR-O-R-PROCEDURES-WITH-CC

    Myeloproliferative Disorders or Poorly Differentiated Neoplasms with Major O.R. Procedures with CC: Inpatient Reimbursement Overview

    828-MYELOPROLIFERATIVE-DISORDERS-OR-POORLY-DIFFERENTIATED-NEOPLASMS-WITH-MAJOR-O-R-PROCEDURES-WITHOUT-CC-MCC

    Myeloproliferative Disorders or Poorly Differentiated Neoplasms: Inpatient Reimbursement Overview

    829-MYELOPROLIFERATIVE-DISORDERS-OR-POORLY-DIFFERENTIATED-NEOPLASMS-WITH-OTHER-PROCEDURES-WITH-CC-MCC

    Myeloproliferative Disorders or Poorly Differentiated Neoplasms: Inpatient Reimbursement Overview

    Showing 1–10 of 27

    References

    1. 1.CPT® Codes and Descriptions. AAPC. Retrieved Aug 11, 2026.Maintains the CPT code set's official descriptions and guidelines, licensed from the American Medical Association, used as the definitional source for CPT codes on this page.
    2. 2.HCPCS Quarterly Update. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's quarterly release of HCPCS Level II codes and short/long descriptors, the source for HCPCS code definitions and update history.
    3. 3.ICD-10-CM Full Code List. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's complete ICD-10-CM diagnosis code list, used to cross-reference diagnosis codes associated with this procedure or service.
    Published by

    Trek Health powers OpenPayer with a leading commercial payer intelligence platform, seamlessly converting fragmented payer data into actionable insights for provider organizations.

    Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.